moa of glp-1 agonists Mechanisms action of GLP-1RA Glucagon-like peptide-1 receptor: mechanisms and

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

Its probably reversible

However, research suggests that a high protein diet and resistance training may help prevent loss of muscle mass during GLP- 1 RA usage

Curious about Microdosing GLP-1

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron